Immunological research in clinical psychiatry: Report on the consensus debate during the 7th expert meeting on psychiatry and immunology

Molecular Psychiatry

Volumn 7, Issue 8, 2002, Pages 822-826

  Arolt, V ^a   Rothermundt, M ^a   Peters, M ^a   Leonard, B ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Autoimmunity; Consensus; Cytokine; Depression; Immune dysfunction; Immunology; Methodology; Methods; Psychoneuroimmunology; Schizophrenia

Indexed keywords

CYTOKINE; NEUROTRANSMITTER;

BRAIN FUNCTION; CONFERENCE PAPER; MEDICAL RESEARCH; MENTAL DISEASE; NEUROBIOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY;

ALLERGY AND IMMUNOLOGY; HUMANS; MENTAL DISORDERS; NEUROIMMUNOMODULATION; PSYCHIATRY;

EID: 0036385409     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001115     Document Type: Article

References (23)

1. Lehmann-Facius H. Liquoruntersuchungen bei destruktiven Erkrankungen des Nervensystems, besonders bei Schizophrenien. Neurol Psychiatrie 1937; 157: 109-115.
2. Stein M, Miller AH, Trestman RL. Depression, the immune system, and health and illness. Findings in search of meaning. Arch Gen Psychiatry 1991; 48: 171-177.
3. Kirch DG. Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 1993; 19: 355-370.
4. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999; 4: 328-332.
5. Capuron L, Ravaud A, Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alpha-2b therapy. J Clin Oncol 2000; 18: 2143-2151.
6. Villemain F, Chatenoud L, Galinowski A, Homo-Delarche F, Ginestet D, Loo H et al. Aberrant T-cell mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 1989; 146: 609-616.
7. Ganguli R, Brar JS, Chengappa KNR, DeLeo M, Yang ZW, Shurin G, Rabin BS. Mitogen-stimulated interleukin-2 production in never-medicated, first episode schizophrenic patients. Arch Gen Psychiatry 1995; 52: 668-671.
8. Arolt V, Rothermundt M, Wandinger KP, Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5: 150-158.
9. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 2000; 11: 3385-3388.
10. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997; 25: 123-129.
11. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993; 150: 1408-1410.
12. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-1297.
13. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 1989; 46: 291-292.
14. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994; 90: 311-315.
15. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 1999; 156: 1103-1104.
16. Müller N, Riedel M, Hadjamu M, Schwarz MJ, Ackenheil M, Gruber R. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999; 156: 634-636.
17. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999: 33: 407-418.
18. Pollmacher T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000; 34: 369-382.
19. Yolken RH, Karlsson H, Yee F, Johnston-Wilson NL, Torrey EF. Endogenous retroviruses and schizophrenia. Brain Res Brain Res Rev 2000; 31: 193-199.
20. van West D, Maes M. Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuroendocrinol Lett 1999; 20: 11-17.
21. Licinio J, Wang ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327.
22. Prolo P, Licinio J. Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999; 4: 396.
23. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 767-780.